http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Park, Younghee,Kim, Kyung Su,Kim, Kyubo,Chie, Eui Kyu,Kim, Jin Ho,Kim, Jae-Sung,Kim, Tae Hyun,Kim, Dae Yong,Jang, Won Il,Kim, Mi-Sook,Koo, Tae Ryool,Chang, Ah Ram M. Nijhoff ; Kluwer Academic Publishers 2015 Journal of neuro-oncology Vol.125 No.2
<P>The incidence of brain metastasis from hepatocellular carcinoma (HCC) is increasing because of the improved survival outcome of HCC patients, but the prognosis of these patients is extremely poor. HCC patients with brain metastasis were investigated to identify their prognostic factors for overall survival. Patients with brain metastasis from HCC who had been treated with whole-brain radiotherapy (WBRT) in five hospitals were enrolled in the study. The medical records of the patients were reviewed, and the clinical factors were analyzed to identify the prognostic factors for overall survival. Of the total of 97 patients who were enrolled in the study, 83 were male and the median age at the brain metastases was 56.6??years. Motor weakness (43.3??%) and headache (41.2??%) were common presenting symptoms. The median AFP level was 4180??ng/ml, and 81 patients were assessed as belonging to Child-Pugh classification A upon the diagnosis of brain metastasis. WBRT alone in 71 patients, surgery or radiosurgery combined with WBRT as the adjuvant setting in 18 patients, and WBRT as salvage treatment in 8 patients were performed. The median overall survival of the patients was 3.5??months. In the multivariate analysis, the ECOG performance status (PS), Child-Pugh classification, AFP, and treatment aim showed significant association with the overall survival of the patients. Based on these factors, a nomogram predicting the prognosis was developed. The concordance index of the nomogram was 0.74, and the prediction was well calibrated. In conclusion, the survival outcome of patients with brain metastasis from HCC can be predicted with the nomogram constructed from the ECOG PS, Child-Pugh classification, AFP, and treatment aim.</P>
Kim, Kyubo,Chie, Eui Kyu,Jang, Jin-Young,Kim, Sun Whe,Han, Sae-Won,Oh, Do-Youn,Im, Seock-Ah,Kim, Tae-You,Bang, Yung-Jue,Ha, Sung W Doyma 2012 Clinical & translational oncology Vol.14 No.5
<P>To analyse the outcome of adjuvant chemoradiotherapy for periampullary adenocarcinoma and the impact of tumour location as a prognosticator.</P>
Kim, Haeyoung,Park, Won,Yu, Jeong Il,Choi, Doo Ho,Huh, Seung Jae,Kim, Yeon-Joo,Lee, Eun Sook,Lee, Keun Seok,Kang, Han-Sung,Park, In Hae,Shin, Kyung Hwan,Wee, Chan Woo,Kim, Kyubo,Park, Kyung Ran,Kim, Y 대한암학회 2017 Cancer Research and Treatment Vol.49 No.4
<P><B>Purpose</B></P><P>This study was conducted to evaluate the impact of supraclavicular lymph node radiotherapy (SCNRT) on N1 breast cancer patients receiving post-lumpectomy whole-breast irradiation (WBI) and anthracycline plus taxane-based (AT) chemotherapy.</P><P><B>Materials and Methods</B></P><P>We performed a case-control analysis to compare the outcomes of WBI and WBI plus SCNRT (WBI+SCNRT). Among 1,147 patients with N1 breast cancer who received post-lumpectomy radiotherapy and AT-based chemotherapy in 12 hospitals, 542 were selected after propensity score matching. Patterns of failure, disease-free survival (DFS), distant metastasis-free survival (DMFS), and treatment-related toxicity were compared between groups.</P><P><B>Results</B></P><P>A total of 41 patients (7.6%) were found to have recurrence. Supraclavicular lymph node (SCN) failure was detected in three patients, two in WBI and one in WBI+SCNRT. All SCN failures were found simultaneously with distant metastasis. There was no significant difference in patterns of failure or survival between groups. The 5-year DFS and DMFS for patients with WBI and WBI+SCNRT were 94.4% versus 92.6% (p=0.50) and 95.1% versus 94.5% (p=0.99), respectively. The rates of lymphedema and radiation pneumonitis were significantly higher in the WBI+SCNRT than in the WBI.</P><P><B>Conclusion</B></P><P>We did not find a benefit of SCNRT for N1 breast cancer patients receiving AT-based chemotherapy.</P>
Kim, Min-Ji,Bae, Soo Han,Ryu, Jae-Chan,Kwon, Younghee,Oh, Ji-Hwan,Kwon, Jeongho,Moon, Jong-Seok,Kim, Kyubo,Miyawaki, Atsushi,Lee, Min Goo,Shin, Jaekyoon,Kim, Young Sam,Kim, Chang-Hoon,Ryter, Stefan W. Informa UK (TaylorFrancis) 2016 AUTOPHAGY Vol.12 No.8
<P>Proper regulation of mitophagy for mitochondrial homeostasis is important in various inflammatory diseases. However, the precise mechanisms by which mitophagy is activated to regulate inflammatory responses remain largely unknown. The NLRP3 (NLR family, pyrin domain containing 3) inflammasome serves as a platform that triggers the activation of CASP1 (caspase 1) and secretion of proinflammatory cytokines. Here, we demonstrate that SESN2 (sestrin 2), known as stress-inducible protein, suppresses prolonged NLRP3 inflammasome activation by clearance of damaged mitochondria through inducing mitophagy in macrophages. SESN2 plays a dual role in inducing mitophagy in response to inflammasome activation. First, SESN2 induces mitochondrial priming by marking mitochondria for recognition by the autophagic machinery. For mitochondrial preparing, SESN2 facilitates the perinuclear-clustering of mitochondria by mediating aggregation of SQSTM1 (sequestosome 1) and its binding to lysine 63 (Lys63)-linked ubiquitins on the mitochondrial surface. Second, SESN2 activates the specific autophagic machinery for degradation of primed mitochondria via an increase of ULK1 (unc-51 like kinase 1) protein levels. Moreover, increased SESN2 expression by extended LPS (lipopolysaccharide) stimulation is mediated by NOS2 (nitric oxide synthase 2, inducible)-mediated NO (nitric oxide) in macrophages. Thus, Sesn2-deficient mice displayed defective mitophagy, which resulted in hyperactivation of inflammasomes and increased mortality in 2 different sepsis models. Our findings define a unique regulatory mechanism of mitophagy activation for immunological homeostasis that protects the host from sepsis.</P>
CD24 expression predicts distant metastasis in extrahepatic bile duct cancer.
Kim, Kyubo,Min, Hye Sook,Chie, Eui Kyu,Jang, Jin-Young,Kim, Sun Whe,Han, Sae-Won,Oh, Do-Youn,Im, Seock-Ah,Kim, Tae-You,Bang, Yung-Jue,Jang, Ja-June,Ha, Sung W WJG Press 2013 World journal of gastroenterology Vol.19 No.9
<P>To evaluate the prognostic significance of CD24 expression in patients undergoing adjuvant chemoradiotherapy for extrahepatic bile duct (EHBD) cancer.</P>
Hak Jae Kim(김학재),Jin Ho Kim(김진호),Kyubo Kim(김규보),Ja Young Choi(최자영),Moon Sang Chung(정문상),Il Han Kim(김일한) 대한방사선종양학회 2007 Radiation Oncology Journal Vol.25 No.4
목 적: 주관절의 이소성 골형성은 수술이나 외상 후에 발생하는 흔한 합병증으로 알려져 있다. 본 연구는 주관절에서 발생하는 이소성 골형성의 재발 방지를 위해 예방적 방사선 치료를 시행한 환자들을 대상으로 후향적 분석을 시행하 였다. 대상 및 방법: 주관절에 이소성 골형성으로 진단된 45명의 환자가 수술 후 방사선 치료를 시행 받았다. 이소성 골형성의 주된 원인은 골절과 외상이었고 수술 전 주된 증상은 가동관절범위의 제한이었다. 방사선 치료는 대부분의 환자에서 수술 후 2일 안에 시작하였고 1일 조사선량을 4 Gy씩 2회에 걸쳐 총 8 Gy를 조사하였다. 29명의 환자에서 1∼8개 월 동안 NSAID를 투약 받았다. 결 과: 치료 후(60∼145o) 측정한 가동관절범위에서 치료 전(0∼135o)보다 통계적으로 유의한 향상을 보였고(p=0.028), MEPI를 이용한 기능지수 평가에서도 치료 전(15∼90)보다 치료 후(80∼100)에서 통계적으로 유의하게 증가하였다. 추적 관찰 시 방사선 사진의 판독이 가능했던 34명의 환자 중 2명에서 경미한 이소성 골형성의 재발이 있는 것으로 나타났다. 치료 후 합병증은 관찰되지 않았다. 결 론: 주관절의 이소성 골형성의 경우 수술 후 예방적 방사선 치료를 시행하는 것은 재발 방지를 위해 유용한 치료로 선택될 수 있고, 향후 더 많은 환자를 대상으로 연구가 진행되어야 할 것으로 생각된다. Purpose: Heterotopic ossification is a well-known postoperative and post-traumatic complication of the elbow. We reviewed the treatment outcome for the use of low-dose radiation after surgical intervention of the elbow to prevent recurrence of heterotopic ossification (HO). Materials and Methods: Forty-five patients with HO underwent surgical intervention and postoperative radiotherapy of the elbow. The median age of the patients was 29 years (16∼75 years), and 27 of the patients were men and 18 were women. The occurrence of HO was mainly due to surgery after fracture (24/45) and traumatic injury (21/45). Limitation of the range of motion (ROM) was the most common symptom of the patients. Thirty-four patients received postoperative radiotherapy with a dose of 8 Gy in 2 fractions; 5 patients received a dose of 10 Gy in 5 fractions and 6 patients received a dose of 7 Gy in 1 fraction. Postoperative radiotherapy was given on the first two postoperative days for most of the patients. Sixteen patients were not given anti-inflammatory medication and 29 patients were given NSAIDs for 1∼8 months. Results: After a median follow-up period of 18 months (range 6∼72 months), 41 patients showed clinical improvement and two patients did not show improvement. Assessment of the ROM showed a mean improvement from 0∼135o to 60∼145o (p=0.028), and assessment of the functional outcome according to MEPI was from (15∼95) to (80∼100) (p<0.0001). Two of the 34 patients that were followed-up with radiography had mild radiological recurrence of heterotopic ossification. No complications were observed after the radiotherapy. Conclusion: These results suggested that low-dose radiation administered after surgical intervention is safe and effective to prevent the recurrence of HO in the elbow.